-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MYMV-101 in Human Immunodeficiency Virus (HIV) Infections (AIDS)...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Company Profile
Mymetics Corp – Company Profile
Mymetics Corp (Mymetics) is a biotechnology company that develops next-generation prophylactic vaccines for life disabling and infectious diseases. The company develops pipeline products based on its proprietary technology platform virosomes with the utilization of rationally designed antigens, natural membrane proteins and lipid based carrier with fusion viral proteins. Its pipeline product includes vaccine candidates that target HIV-1/AIDS, chikungunya, intra nasal influenza, malaria, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). Mymetics vaccines are designed for protection against early transmission...
Add to Basket -
Sector Analysis
Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Report Overview Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. Influenza infection is normally self-limiting. Symptoms generally last for one to two weeks, but most people infected with influenza do not need or seek medical treatment. The Seasonal Influenza Therapeutics (SIT) marketed and pipeline drugs market research report provides a data-driven overview...
-
Track & Monitor
Innovation in Pharmaceuticals: HIV peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s HIV peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Innovation in Pharmaceuticals: Multivalent veterinary vaccines
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
Innovation in Pharmaceuticals: rtRNA virus peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s rtRNA virus peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MYMV-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MYMV-101 Drug Details MYM-V101 (HIV-1 vaccine) is under development for the prevention of HIV-1...
-
Product Insights
Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Glycoprotein 41 pipeline drugs market research report outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.
-
Product Insights
Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. The Malaria pipeline market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and...